Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donna Neuberg

Showing results (111-120 of 354) with videos related to

Pageof 36
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2007
MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancerRebecca Suk Heist, Wei Zhou, Lucian R Chirieac, et al.
Neurology|July 31, 2013
Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatmentNicole J Ullrich, Mark W Kieran, David T Miller, et al.
Leukemia Research|January 18, 2006
Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997Larry D Cripe, Kevin Rader, Martin S Tallman, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 2, 2002
ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destructionF Stephen Hodi, Jan C Schmollinger, Robert J Soiffer, et al.
Leukemia & Lymphoma|May 15, 2015
Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemiaJennifer R Brown, Bethany Tesar, Lijian Yu, et al.
Leukemia & Lymphoma|April 7, 2010
Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients who failed cyclophosphamide, adriamycin, vincristine, and prednisoneYi-Bin Chen, Ephraim P Hochberg, Yang Feng, et al.
The New England Journal of Medicine|July 1, 2011
Clinical effect of point mutations in myelodysplastic syndromesRafael Bejar, Kristen Stevenson, Omar Abdel-Wahab, et al.
American Journal of Hematology|July 14, 2020
Heparin induced thrombocytopenia antibodies in Covid-19Rushad Patell, Adeel M Khan, Thomas Bogue, et al.
Blood Advances|May 23, 2020
Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trialJeffrey I Zwicker, Joanna Roopkumar, Maneka Puligandla, et al.
Leukemia|February 26, 2022
Antibody and T-cell responses to SARS-CoV-2 vaccination in myeloproliferative neoplasm patientsJoan How, Kathleen M E Gallagher, Yiwen Liu, et al.
Pageof 36

Showing results (111-120 of 354) with videos related to

Sort By:
Pageof 36
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2007
MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancerRebecca Suk Heist, Wei Zhou, Lucian R Chirieac, et al.
Neurology|July 31, 2013
Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatmentNicole J Ullrich, Mark W Kieran, David T Miller, et al.
Leukemia Research|January 18, 2006
Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997Larry D Cripe, Kevin Rader, Martin S Tallman, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 2, 2002
ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destructionF Stephen Hodi, Jan C Schmollinger, Robert J Soiffer, et al.
Leukemia & Lymphoma|May 15, 2015
Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemiaJennifer R Brown, Bethany Tesar, Lijian Yu, et al.
Leukemia & Lymphoma|April 7, 2010
Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients who failed cyclophosphamide, adriamycin, vincristine, and prednisoneYi-Bin Chen, Ephraim P Hochberg, Yang Feng, et al.
The New England Journal of Medicine|July 1, 2011
Clinical effect of point mutations in myelodysplastic syndromesRafael Bejar, Kristen Stevenson, Omar Abdel-Wahab, et al.
American Journal of Hematology|July 14, 2020
Heparin induced thrombocytopenia antibodies in Covid-19Rushad Patell, Adeel M Khan, Thomas Bogue, et al.
Blood Advances|May 23, 2020
Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trialJeffrey I Zwicker, Joanna Roopkumar, Maneka Puligandla, et al.
Leukemia|February 26, 2022
Antibody and T-cell responses to SARS-CoV-2 vaccination in myeloproliferative neoplasm patientsJoan How, Kathleen M E Gallagher, Yiwen Liu, et al.
Pageof 36